此前在 美敦力（2004–2023） 任职近20年 ，最终担任美洲地区副总裁 ，主导糖尿病家庭护理业务的支付策略与市场准入。其领导的跨职能团队涵盖 销售、临床支 持、健康经济学、报销、客户服务与营销 等关键部门，具备丰富的跨区域管理经验。 | 思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | | | | | | --- | --- | --- | --- | --- | --- | --- | | 即将召开： | | | | | | | | 2025年6月12日，首届全球医美科技大会 | | | | | | | | 2025年7月17日，第二届全球医疗科技大会 | | | | | | | | 2025年9月4-5日，第三届全球手术机器人大会 | | | | | | | | 2025年5月19日 ， 康复护理公司 | Lifeward（纳斯达克代码：LFWD） | 宣布任命 | 前美敦力美洲区副总裁Mark Grant 为公司新任 | 总裁兼首席执行官 | ，自 | 2025年6月2日 | | 起正式生效。此次任命标志着Lifeward进入从技术验证向商业增长过渡的关键阶段 ...

Core Viewpoint - Lifeward Ltd. has appointed Mark Grant as the new President and CEO, effective June 2, 2025, to lead the company in its next growth phase, while outgoing CEO Larry Jasinski will assist in the transition [1][2][3] Company Leadership - Mark Grant brings 30 years of experience in commercial leadership and strategic solutions, having managed teams across multiple geographies and critical functions [2][5] - The Board of Directors expressed confidence in Grant's ability to drive innovations that improve the lives of individuals with physical limitations [3][4] Recent Achievements - Lifeward has made significant progress in the past year, including achieving Medicare payment for the ReWalk exoskeleton and building a strong pipeline of ReWalk cases [3][4] Product Portfolio - The ReWalk exoskeleton is highlighted as a key product in Lifeward's portfolio, which includes other innovative solutions aimed at enhancing the quality of life for individuals with disabilities [4][10] Inducement Grant - In connection with Grant's appointment, Lifeward's Board approved an inducement award of 400,000 options to purchase ordinary shares, subject to specific terms and conditions [8][9] Company Background - Lifeward, founded in 2001, operates in the United States, Israel, and Germany, focusing on developing life-changing solutions for physical rehabilitation and recovery [10][11]

Company Performance - Lifeward reported a quarterly loss of $0.46 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.33, but an improvement from a loss of $0.73 per share a year ago [1] - The company's revenues for the quarter ended March 2025 were $5.03 million, missing the Zacks Consensus Estimate by 16.24% and down from $5.28 million year-over-year [3] - Over the last four quarters, Lifeward has surpassed consensus EPS estimates only once and has missed revenue estimates three times [2][3] Market Performance - Lifeward shares have declined approximately 16.8% since the beginning of the year, contrasting with the S&P 500's gain of 0.2% [4] - The current Zacks Rank for Lifeward is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [7] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $6.47 million, and for the current fiscal year, it is -$0.77 on revenues of $29.02 million [8] - The estimate revisions trend for Lifeward is mixed, and future earnings expectations will depend on management's commentary during the earnings call [4][5] Industry Context - Lifeward operates within the Zacks Internet - Software industry, which is currently ranked in the top 31% of over 250 Zacks industries [9] - The performance of Lifeward's stock may be influenced by the overall outlook for the industry, as top-ranked industries tend to outperform lower-ranked ones significantly [9]

Lifeward (LFWD) Q1 2025 Earnings Call May 15, 2025 08:30 AM ET Company Participants Mike Lawless - CFOLarry Jasinski - CEOBen Haynor - Managing Director Conference Call Participants Yale Jen - Senior Managing Director & Senior Biotech AnalystSwayampakula Ramakanth - Managing Director & Senior Equity Analyst Operator Good day, and welcome to the Q1 twenty twenty five LifeForward, Inc. Earnings Conference Call. All participants will be in listen only mode. Please note this event is being recorded. I would now ...

Financial Data and Key Metrics Changes - Q1 2025 revenues were $5 million, down $300,000 year on year, but the LIFO business was up year on year [5][12] - On a non-GAAP basis, adjusted operating loss was $4.6 million compared to $5.5 million for the same periods [19] - GAAP gross margin was 42.2% compared to 26.4% in Q1 2024, while non-GAAP adjusted gross margin was 42.2% compared to 33.7% [17][18] Business Line Data and Key Metrics Changes - Revenue from ReWalk robotics products was $1.6 million, while Alter G products generated $3.4 million, with Alter G sales growing by 19% year on year [14] - The number of ReWalk rentals increased to 36, primarily in Germany, indicating strong future sales potential [6][15] - Alter G has shown significant growth of 1970% in the last two quarters [7] Market Data and Key Metrics Changes - The U.S. pipeline has over 120 qualified leads, up over 70% from two quarters ago [6][15] - The company has expanded partnerships with Alter G distributors, including four new business partners [6] Company Strategy and Development Direction - The company is focused on profitable revenue growth, tight expense control, and cash management [5] - A partnership with CoreLife aims to enhance progress in the workers' compensation segment [6] - The company anticipates a sales range of $28 million to $30 million for 2025, with expectations of a reduced operating loss by Q4 [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in future growth based on a strong pipeline and recent FDA approvals [6][20] - The leadership transition is expected to be smooth, with a solid foundation in place for future growth [11] Other Important Information - The company ended Q1 with $5.7 million in cash and equivalents and no debt, raising an additional $500,000 post-quarter [19] - The company is working collaboratively with Medicare Administrative Contractors to improve claims processing predictability [10] Q&A Session Questions and Answers Question: What is the assessment of recent tariff situations? - The company is monitoring the situation closely and has planned for alternatives within the market, with minimal impact expected on the ReWalk production in Israel [25][26] Question: How does the company support its full-year revenue guidance despite lower Q1 revenue? - Confidence is based on strong momentum in the Ultra G product line and a robust pipeline of leads, indicating growth potential [28] Question: Can you elaborate on the ReWalk seven's differences from the previous version? - The ReWalk seven features significant improvements in usability, power, and control, while maintaining a similar price point [36][39] Question: How does the expanded Mylan partnership benefit the commercial sales force? - The partnership allows access to a new segment for home use, leveraging historical data to drive sales [42] Question: What is the market size for workers' compensation in the U.S.? - The workers' compensation market represents about 6% to 7% of the overall market, providing a significant opportunity for growth [47] Question: How has the Alter G acquisition performed? - The integration has stabilized, and recent product launches have shown strong growth, particularly in international markets [54][56]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 Lifeward Ltd. (Exact name of registrant as specified in charter) | Israel | | --- | | Not applicable | (State or other jurisdiction ...

Core Insights - Lifeward Ltd. reported a revenue of $5.0 million for Q1 2025, a decrease from $5.3 million in Q1 2024, primarily due to lower sales of ReWalk Exoskeletons and MyoCycles [4][9] - The company experienced a significant increase in gross margin to 42.2% in Q1 2025, up from 26.4% in Q1 2024, attributed to a favorable mix of payors and higher sales volume of AlterG systems [5][29] - Lifeward's operating loss improved to $4.9 million in Q1 2025 from $6.5 million in Q1 2024, indicating better cost management and operational efficiency [8][9] Financial Performance - Revenue from AlterG products and services increased by 17% to $3.3 million in Q1 2025, driven by higher international demand [4] - Operating expenses decreased to $7.0 million in Q1 2025 from $7.9 million in Q1 2024, reflecting cost savings from the closure of certain facilities [6][7] - The net loss narrowed to $4.8 million, or $0.46 per share, compared to a net loss of $6.3 million, or $0.73 per share, in the prior year [9][23] Market Developments - Lifeward launched the ReWalk 7 exoskeleton in the U.S. market following FDA clearance, marking a significant product advancement [6] - The company secured its first approval for a ReWalk 7 claim from a major U.S. commercial health insurance provider, expanding its market reach beyond Medicare [6] - Lifeward established a partnership with CorLife for exclusive distribution of the ReWalk Personal Exoskeleton to individuals with workers' compensation claims, aiming for greater market penetration [6] Liquidity and Guidance - As of March 31, 2025, Lifeward had $5.7 million in unrestricted cash and cash equivalents, with no debt, indicating a stable liquidity position [10] - The company expects full-year revenue for 2025 to be in the range of $28 million to $30 million, reflecting optimistic growth prospects [11]

Core Viewpoint - Lifeward Ltd. is set to release its first quarter 2025 financial results on May 15, 2025, before market opening, indicating a focus on transparency and communication with investors [1]. Company Overview - Lifeward is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [1]. - The company designs, develops, and commercializes solutions that provide functional and health benefits across various care settings, including clinical environments and home care [3]. - Lifeward's product portfolio includes notable innovations such as the ReWalk Exoskeleton, AlterG Anti-Gravity system, MyoCycle FES System, and ReStore Exo-Suit, showcasing its commitment to driving innovation in rehabilitation [3]. Financial Communication - The CEO Larry Jasinski and CFO Mike Lawless will host a conference call and live webcast on May 15, 2025, at 8:30 a.m. EDT to discuss the financial results, emphasizing the company's commitment to engaging with analysts and investors [2]. - Access to the conference call will be available through multiple channels, including toll-free numbers for various regions and a live webcast on the company's website [2].

Core Insights - Lifeward Ltd. has received approval from a major U.S. health insurance company for the ReWalk 7 Personal Exoskeleton, marking a significant step in expanding access for individuals with spinal cord injuries (SCI) [1][2] - The approval follows the Centers for Medicare & Medicaid Services (CMS) establishing a reimbursement pathway for personal exoskeletons in 2024, which is expected to enhance access for Medicare beneficiaries, who represent about one-third of individuals living with SCI [2][3] Company Overview - Lifeward is a leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities, with a mission to drive innovation in rehabilitation and recovery [4] - The company has launched the ReWalk 7, a device designed to assist paralyzed individuals in standing, walking, and navigating everyday environments [3][4] Market Context - The decision by a major commercial health insurer to cover the ReWalk 7 is seen as a pivotal moment that could encourage other insurers to follow suit, thereby solidifying Lifeward's growth trajectory [2][3] - The ReWalk 7 received FDA clearance in March 2025 and was launched for sales in the U.S. on April 15, 2025, indicating a timely entry into the market [1][3]

Core Viewpoint - Lifeward Ltd. has launched the ReWalk 7 Personal Exoskeleton in the U.S., enhancing assistive technology for individuals with spinal cord injuries, showcasing the company's leadership and technological advancements in the industry [1][2][5]. Product Launch and Market Impact - The ReWalk 7 received FDA clearance in March 2025 and follows the ReWalk 6.0 system, which improved user capabilities for navigating stairs and curbs [2]. - The introduction of a Medicare reimbursement pathway in 2024 has facilitated broader market access for the ReWalk 7, supporting Lifeward's mission to empower the spinal cord injury community [2][5]. Technological Enhancements - The ReWalk 7 features cloud connectivity for data-driven updates, two customizable walking speeds, and a new crutch control unit for enhanced user control [7]. - Complementary devices, including a wrist control smartwatch and a mobile application, simplify mode selection and progress tracking, integrating the device into daily routines [7]. User-Centric Development - Lifeward collaborated with over two dozen end users and physical therapists to gather feedback, leading to improvements in training efficiency and safety [9]. - The development process included the introduction of a therapist handheld device for better session control, resulting in a device that enhances user confidence and control [9]. Financial Performance - Following the launch announcement, LFWD's shares increased by 1.4% on April 15, although the company has experienced an 18% decline in shares year-to-date, compared to an 11.1% decline in the industry and an 8.4% drop in the S&P 500 Index [4].